Director/PDMR Shareholding

RNS Number : 7199S

Hutchison China Meditech Limited

21 March 2016

 

Director's Shareholding

London: Monday, March 21, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM / Nasdaq: HCM) received notification on 18 March 2016 that Ms Edith Shih, Non-executive Director, has purchased 40,741 American Depositary Shares ("ADSs", each represents one-half of one ordinary share) of the Company at a price of US$13.50 per ADS on 17 March 2016. 

Following this purchase, Ms Shih is beneficially interested in 40,741 ADSs and 60,000 ordinary shares, representing approximately 0.13% of the current issued share capital of Chi-Med.

Ends

Contact

Investor Enquiries
Christian Hogg, CEO	[phone]
International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson	[phone] (Mobile)
US Based Media Enquiries
Brad Miles, BMC Communications	[phone]
Susan Duffy, BMC Communications	[phone]
Investor Relations
Jillian Connell, The Trout Group	[phone]
David Dible, Citigate Dewe Rogerson	[phone] [phone] (Mobile)
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts	[phone]

 

Notes to Editors

About Chi-Med

Chi-Med is a China-based, globally-focused healthcare group which researches, develops, manufactures and sells pharmaceuticals and health-related consumer products.  Its Innovation Platform focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market.  Its Commercial Platform manufactures, markets and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001).  For more information, please visit: www.chi-med.com.

 

END

 

 

RDSGIGDXGUDBGLB